[1] Bureau of Disease Prevention and Control, National Health Commission. Notice on launching the national cancer prevention and control publicity week in 2020. http://www.nhc.gov.cn/jkj/s5878/202003/8f30acddc9f84132a414233e8937d431.shtml. [2020-03-23]. (In Chinese)http://www.nhc.gov.cn/jkj/s5878/202003/8f30acddc9f84132a414233e8937d431.shtml
[2] International Agency for Research on Cancer. Globocan 2018. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. [2020-03-26].https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf
[3] Liu YN, Wang W, Liu JM, Yin P, Qi JL, You JL, et al. Cancer mortality — China, 2018. China CDC Weekly 2020; 2(5): 63-8. http://weekly.chinacdc.cn/en/article/id/c0c80048-e7c9-4a87-857a-6de538985d15.http://weekly.chinacdc.cn/en/article/id/c0c80048-e7c9-4a87-857a-6de538985d15
[4] Schü z J, Espina C, Wild CP. Primary prevention: a need for concerted action. Mol Oncol 2019;13(3):567 − 78. http://dx.doi.org/10.1002/1878-0261.12432CrossRef
[5] Romero Y, Trapani D, Johnson S, Tittenbrun Z, Given L, Hohman K, et al. National cancer control plans: a global analysis. Lancet Oncol 2018;19(10):e546 − 55. http://dx.doi.org/10.1016/S1470-2045(18)30681-8CrossRef
[6] Serrano D, Bonanni B, Brown K. Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer. Mol Oncol 2019;13(3):579 − 90. http://dx.doi.org/10.1002/1878-0261.12461CrossRef
[7] Wild CP, Espina C, Bauld L, Bonanni B, Brenner H, Brown K, et al. Cancer prevention Europe. Mol Oncol 2019;13(3):528 − 34. http://dx.doi.org/10.1002/1878-0261.12455CrossRef
[8] Gapstur SM, Drope JM, Jacobs EJ, Teras LR, McCullough ML, Douglas CE, et al. A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. CA: A Cancer J Clin 2018;68(6):446 − 70. http://dx.doi.org/10.3322/caac.21496CrossRef
[9] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer J Clin 2020;70(1):7 − 30. http://dx.doi.org/10.3322/caac.21590CrossRef
[10] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer J Clin 2019;69(1):7 − 34. http://dx.doi.org/10.3322/caac.21551CrossRef
[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer J Clin 2018;68(1):7 − 30. http://dx.doi.org/10.3322/caac.21442CrossRef
[12] Alcaraz KI, Wiedt TL, Daniels EC, Yabroff RK, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy. CA: A Cancer J Clin 2020;70(1):31 − 46. http://dx.doi.org/10.3322/caac.21586CrossRef
[13] National Administration of Traditional Chinese Medicine. Healthy China Initiative - cancer prevention and control implementation plan (2019−2022). China Cancer 2019;28(11):803−6. http://www.chinaoncology.cn/zgzl8/ch/reader/view_abstract.aspx?doi=10.11735/j.issn.1004-0242.2019.11.A001. (In Chinese)http://www.chinaoncology.cn/zgzl8/ch/reader/view_abstract.aspx?doi=10.11735/j.issn.1004-0242.2019.11.A001
[14] Cuzick J. Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. Br J Cancer 2018;118(9):1155 − 61. http://dx.doi.org/10.1038/s41416-018-0039-4CrossRef
[15] Kirby T. David Whiteman: harnessing the power of cancer prevention. Lancet 2018;392(10148):628. http://dx.doi.org/10.1016/S0140-6736(18)31804-XCrossRef
[16] Ilbawi AM, Ayoo E, Bhadelia A, Chidebe RCW, Fadelu T, Herrera CA, et al. Advancing access and equity: the vision of a new generation in cancer control. Lancet Oncol 2017;18(2):172 − 5. http://dx.doi.org/10.1016/S1470-2045(17)30041-4CrossRef